Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: Identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface

Journal of Immunology

Volumn 167, Issue 10, 2001, Pages 5758-5766

  Guthridge, J M ^a   Young, K ^a   Gipson, M G ^a   Sarrias, M R ^a   Szakonyi, G ^a   Chen, X S ^a   Malaspina, A ^a   Donoghue, E ^a   James, J A ^a   Lambris, J D ^a   Moir, S A ^a   Perkins, S J ^a   Holers, V M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; EPITOPE; GLYCOPROTEIN GP220; GLYCOPROTEIN GP350; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; X RAY CRYSTALLOGRAPHY;

EID: 0035889946     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.10.5758     Document Type: Article

References (52)

1. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21)
2. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment
3. The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity
4. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody
5. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2
6. r membrane protein as the C3d receptor (CR2) of human B lymphocytes
7. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2
8. Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2)
9. CD21 is a ligand for CD23 and regulates IgE production
10. The regulators of complement activation (RCA) gene cluster
11. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen
12. Antibody response to a T-dependent antigen requires B cell expression of complement receptors
13. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2
14. The complement system and adaptive immunity
15. CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes
16. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
17. CD21 augments antigen presentation in immune individuals
18. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes
19. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal center B cells: Evidence for bifurcation in the development of centrocytes rescued from apoptosis
20. + T cell clones
21. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis
22. Epstein-Barr virus infection
23. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus
24. Rheumatoid arthritis and Epstein-Barr virus: A case of living with the enemy?
25. Epstein-Barr virus and multiple sclerosis
26. T lymphocyte expression of complement receptor 2 (CR2/CD21): A role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE)
27. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus
28. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2;CD21): Expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice
29. A critical role for complement in maintenance of self-tolerance
30. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses
31. Binding of HIV type-1 to follicular dendritic cells in vitro is complement-dependent
32. Follicular dendritic cells and human immunodeficiency virus infectivity
33. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2
34. Expression of EBV/C3d receptors on T cells: Biological significance
35. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion
36. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells
37. Characterization of C3dg binding to a recess formed between SCR 1 and SCR 2 of complement receptor type 2
38. -/- mice is rescued by adjuvants without improvement in germinal center development
39. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor 2
40. Structure of complement receptor 2 in complex with its C3d ligand
41. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg
42. Induction of peri-insulitis but not diabetes in islet transplants expressing a single foreign antigen: A multistage model of disease
43. Structural requirements for C3dg/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection
44. Expression of C3d receptors during human B cell differentiation: Immunofluorescence analysis with the HB-5 monoclonal antibody
45. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells
46. Characterization of a complement receptor 2 (CD2, CD21) ligand binding site for C3: An initial model of ligand interaction with two linked SCR modules
47. Linear epitope mapping of an Sm B/B′ protein
48. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons
49. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides
50. Strategies for epitope analysis using peptide synthesis
51. Anti-Ro fine specificity defined by multiple antigenic peptides identifies components of tertiary epitopes
52. Human lupus anti-spliceosome A autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns